Stay updated on Relatlimab Safety in B-Cell Malignancies Clinical Trial
Sign up to get notified when there's something new on the Relatlimab Safety in B-Cell Malignancies Clinical Trial page.

Latest updates to the Relatlimab Safety in B-Cell Malignancies Clinical Trial page
- Check3 days agoChange DetectedRecruitment status is updated to 'No longer looking for participants', indicating enrollment for the study has ended. Additional edits add new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study) and adjust the Intervention/Treatment labeling and a site revision note, reflecting formatting and navigational updates.SummaryDifference0.4%

- Check10 days agoChange DetectedRevision: v3.5.5 has been added to the page, replacing the previous Revision: v3.5.4.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check32 days agoChange DetectedThe page’s revision label has been updated from v3.5.3 to v3.5.4, indicating a maintenance update; the study content and structure remain the same.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page revision/version indicator was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check60 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check82 days agoChange DetectedB-cell chronic lymphocytic leukemia was added to the study's list of conditions.SummaryDifference0.0%

Stay in the know with updates to Relatlimab Safety in B-Cell Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Relatlimab Safety in B-Cell Malignancies Clinical Trial page.